Skip to main content
Funded Studies

Adrian Newman-Tancredi, PhD, DSc

Chief Executive Officer at Neurolixis

Location: Park Ridge, NJ United States

Adrian Newman-Tancredi, PhD, DSc, has over 25 years of experience in pharma industry neuroscience research and drug discovery. Prior to joining Neurolixis, he was director of neurobiology at Pierre Fabre, where he led multi-disciplinary programs that successfully identified novel central nervous system (CNS) drugs. Prior to Pierre Fabre, Dr. Newman-Tancredi led a molecular pharmacology team at Servier, where he investigated signal transduction mechanisms of monoamine receptors. Drugs characterized in the course of Dr. Newman-Tancredi's work include milnacipran (Savella), piribedil (Trivastal), agomelatine (Valdoxan), levomilnacipran (Fetzima) and the serotonergic ‘biased agonist,’ NLX-101.

Dr. Newman-Tancredi leads the development program on NLX-112 (befiradol), a drug candidate for treatment of levodopa-induced dyskinesia. Dr. Newman-Tancredi has published over 170 research reports, co-authored patents on new chemical entities (NCEs) and given presentations to a wide variety of audiences. He received his BSc with honors in biochemistry, followed by a PhD and a DSc in neuropharmacology, from the University of Kent at Canterbury, United Kingdom.



Associated Grants

  • Safety and Tolerability of NLX-112 in People with Parkinson’s


  • Anti-dyskinetic Activity of the Selective 5-HT1A Agonist NLX-112: Behavioral and Microdialysis Studies


  • Predicting the Efficacious Dose of the Selective 5-HT1A Agonist NLX-112


  • Preferential Targeting of Subpopulations of 5-HT1A Receptors: Microdialysis Study


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.